Validation of assay procedure of rizatriptan bioequivalence studies of generics according to biowaiver procedure

Authors

  • S. Yu. Visich National University of Pharmacy, Institute for Advanced Studies of pharmacy professionals NUPh, Ukraine
  • A. V. Dorovsky National University of Pharmacy, Institute of Pharmacy Professionals Qualification Improvement of NUPh, Ukraine
  • E. G. Fetisova National University of Pharmacy, Institute of Pharmacy Professionals Qualification Improvement of NUPh, Ukraine
  • L. M. Andryukova National University of Pharmacy, Institute of Pharmacy Professionals Qualification Improvement of NUPh, Ukraine

DOI:

https://doi.org/10.24959/ubphj.17.137

Keywords:

Rizatriptan, validation, liquid chromatography, bioequivalence, biowaiver, pH-dependent solubility, dissolution in vitro

Abstract

Topicality. Proof of bioequivalence of generic and reference drugs according to biovaser procedure based on the BCS for simplified registration provides for determination of solubility of active substance for establishing the BCS class and kinetics of its release from test drugs in three buffer media. These studies should be carried out according to developed and validated assay methods of active substance.Aim. To establish validation performance of assay methods of Rizatriptan in a complex of studies on determination of bioequivalence of Rizatriptan drugs in form of tablets 5 mg and 10 mg according to biowaiver procedure.
Materials and methods. Validation was carried out for assay methods of Rizatriptan simultaneously studying pH-dependent solubility and kinetics of release of active substance from generic and reference drugs in three buffer media. The study was performed in range of 25-125 % of nominal content of Rizatriptan in test solution in accordance with requirements of SPU in three buffer media according to main validation parameters: full predictable uncertainty of analysis results, specificity, accuracy, repeatability, linearity.
Results and discussion. Correspondence of validation performance to the acceptance criteria in all dissolution media was established.
Conclusions. Based on results of validation, it was justified and experimentally proved that assay methods of Rizatriptan are suitable for analytical support of in vitro bioequivalence studies of MP containing Rizatriptan.

Author Biographies

S. Yu. Visich, National University of Pharmacy, Institute for Advanced Studies of pharmacy professionals NUPh

Applicant at the Department of Industrial Pharmacy and Economics Department

A. V. Dorovsky, National University of Pharmacy, Institute of Pharmacy Professionals Qualification Improvement of NUPh

Head of Industrial Pharmacy and Economics Department, doctor of Economics, professor

E. G. Fetisova, National University of Pharmacy, Institute of Pharmacy Professionals Qualification Improvement of NUPh

Associate Professor of Industrial Pharmacy and Economics Department, candidate of Pharmaceutical Sciences (PhD), associate professo

L. M. Andryukova, National University of Pharmacy, Institute of Pharmacy Professionals Qualification Improvement of NUPh

Associate Professor of Industrial Pharmacy and Economics Department, doctor of Pharmaceutical Sciences, senior research officer

References

Zakon Ukrainy. Pro likarski zasoby. Available at: http://zakon2.rada.gov.ua/laws/show/123/96–вр/page

Tarasenko, O. O. (2014). Problemy ekolohichnoi ta medychnoi henetyky i klinichnoi imunolohii, 4, 182–198.

Derzhavna Farmakopeia Ukrainy, 2nd ed. (2015). Kharkiv: Naukovo–ekspertnyi farmakopeinyi tsentr, 1128.

ST–N MOZU 42–7.1:2016. Likarski zasoby. Doslidzhennia bioekvivalentnosti (2016). Kyiv: MOZ Ukrainy, 79.

Downloads

Published

2017-10-17

Issue

No. 5(52) (2017)

Section

Biopharmaceutical research

License

Copyright (c) 2017 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).